11:59 AM EST - QLT Inc. : announced results of its Phase II clinical study on the efficacy and safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) and open-angle glaucoma (OAG). QLT Inc.
shares T.QLT are trading up $0.52 at $6.82.
